• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
      • Project Deliverables
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • For Research Participants
    • Why Participate in EPAD?
      • EPAD & Dementia Research
      • Our Progress
    • Participation in EPAD Trials
    • EPAD Cohort Study
      • Trial Locations
      • EPAD Study Visits
    • EPAD Stories
    • Participation FAQs
  • For Intervention Owners
    • The EPAD Platform
      • Terms of Reference
    • EPAD Benefits
    • Clinical Candidate Selection
      • EPAD Application Process
    • EPAD FAQs
    • Research Resources
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Events
Menu back  

EPAD passes the mark of 1,000 participants for its Longitudinal Cohort Study

2018-09-21News

The members of the EPAD initiative are glad to announce that its Longitudinal Cohort Study has recruited its 1,000th participant at the University of Oxford (UK) this 21st September on World Alzheimer’s Day.

EPAD is one of the world leading dementia prevention studies, led from the University of Edinburgh. It is a Europe-wide collaboration aiming to improve the understanding of the early stages of Alzheimer’s disease. It combines knowledge and expertise from 38 European organisations from academia and industry, bringing together a wealth of experience to its activities and making it the largest ever public-private partnership in Alzheimer’s disease research. The EPAD project offers a unique platform for testing and developing preventative treatments for Alzheimer’s dementia.

This new approach of tackling the global concern of dementia has reached a milestone where the EPAD Cohort has screened more than 1,000 research participants.

“We want to stand with the young academics and researchers helping to find a cure or amelioration for dementia”, said a research participant in the EPAD study.

EPAD is set up to recruit from existing cohort studies as well as clinics across Europe. EPAD has established the first pan-European register including more than 30,000 research participants aged 50 or over across the dementia risk spectrum. From this register, individuals who do not have dementia are invited to join the EPAD Cohort study, involving regular health checks, standardised tests and brain scans. All participants are followed up over several years.

Many participants in the EPAD Cohort study may be invited to participate in the EPAD Proof of Concept Trial to test new treatments for the prevention of Alzheimer’s dementia. 

“Recruiting from the EPAD Cohort allows us to select the right people for the drug studies who are most likely to benefit from them. We are very grateful to have reached 1,000 participants in this globally important project”, said Professor Craig Ritchie, EPAD Co-coordinator.

Participants in the EPAD Cohort are contributing to the advancement of science around dementia prevention in 20 locations across 7 European countries (i.e. France, Italy, the Netherlands, Spain, Switzerland, Sweden and UK) and more sites to join soon.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Interview with Sammy Danso
2019-01-24
Interview with Marija Jovanovic
2019-01-24
Spotlight on Grampian
2019-01-24
Interview with Alejandro Laquidain
2019-01-17
EPAD turns four!
2019-01-15
EPAD publishes its LCS study protocol
2018-12-27
Latest News
  • Interview with Sammy Danso
    2019-01-24
  • Interview with Marija Jovanovic
    2019-01-24
  • Spotlight on Grampian
    2019-01-24
  • Interview with Alejandro Laquidain
    2019-01-17
  • EPAD turns four!
    2019-01-15
Subscribe to our Newsletter

View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

"I hope that the #EPADAcademy will become a close circle of #researchers who will be providing support to nourish a new generation of academics in the field of #dementia" said #EPADFellow @stina_saunders Check out the newly #EPADAcademy tab on our website: ep-ad.org/epad-academy/ pic.twitter.com/8xRBkuDL3l

reply retweet favorite
10:02 am · 2019-02-19
Twitter
EPAD
EPAD
@IMI_EPAD

Who are we and what are we doing? Read recent interviews with #epadistas on our website to find out more: ep-ad.org/news-publicati… pic.twitter.com/cOp2eueOpa

reply retweet favorite
9:49 am · 2019-02-19
Twitter
EPAD
EPAD
@IMI_EPAD

Happy to inform that Deliverable D1.6 "Interim report on evaluation of #biomarker and #clinical #assessments and #outcomes from existing and acquired #data" was submitted to @IMI_JU last month. ep-ad.org/about/project-… pic.twitter.com/SgyZMYXA7q

reply retweet favorite
7:49 am · 2019-02-18
Twitter
EPAD
EPAD
@IMI_EPAD

José Luis Molinuevo (@fpmaragall) mentioned @IMI_EPAD in this spanish report published in the newspaper El País. "We participate in the EPAD project, a consortium between the academic and the private sector to design more efficient Phase II trials" elpais.com/elpais/2019/02… twitter.com/fpmaragall/sta…

reply retweet favorite
10:00 am · 2019-02-14
Twitter
EPAD
EPAD
@IMI_EPAD

.@IMI_EPAD Longitudinal Cohort Study recruitment Update ⤵️ We currently have 21 European sites enrolling and 1450 research participants screened. @IMI_JU @EFPIA @EU_H2020

reply retweet favorite
8:27 am · 2019-02-13
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More